PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD
摘要:
The present disclosure relates generally to PROTAC (proteolysis-targeting chimera) compounds, pharmaceutical compositions comprising such compounds, and methods of treating various diseases and conditions with such compounds.
3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
申请人:Xue Chu-Biao
公开号:US20070149532A1
公开(公告)日:2007-06-28
The present invention is directed to compounds of Formula I:
I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators
申请人:Ares Trading SA
公开号:EP2508526A1
公开(公告)日:2012-10-10
The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.
[EN] SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE SPIROALCÈNECARBOXAMIDE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE CHEMOKINES
申请人:ARES TRADING SA
公开号:WO2012130915A1
公开(公告)日:2012-10-04
The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.
3-aminocyclopentanecarboxamides as modulators of chemokine receptors
申请人:Xue Chu-Biao
公开号:US20060020133A1
公开(公告)日:2006-01-26
The present invention is directed to compounds of Formula I:
which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
申请人:Xue Chu-Biao
公开号:US20100203039A1
公开(公告)日:2010-08-12
The present invention is directed to compounds of Formula I:
which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.